Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurlan, R.
Right arrow Articles by Shoulson, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurlan, R.
Right arrow Articles by Shoulson, I.
NEUROLOGY 1985;35:738
© 1985 American Academy of Neurology

Long-term experience with pergolide therapy of advanced parkinsonism

Roger Kurlan, MD, Charlyne Miller, RN, MS, Robert Levy, MD, Bernard Macik, MD, Robert Hamill, MD and Ira Shoulson, MD

Department of Neurology, University of Rochester Medical Center, Rochester, NY.

Nine patients with idiopathic Parkinson's disease were treated with pergolide to a daily maintenance dose of 2.2 ± 0.9 mg (mean ± SD) for 17.3 ± 8.3 months. After 1 month, there was an average 68% increase in mobile on-time, but the improvement declined to 30% by 6 months, 23% by 1 year, and virtually disappeared by 18 months of therapy. Pergolide was discontinued in seven patients because of loss of efficacy (4 patients), confusion (1 patient), or myocardial infarction or ventricular ectopy (2 patients). Partial but temporary restoration of mobility was observed in seven patients who were switched to an alternate-day dosing schedule after 9.2 ± 2.4 months. Two patients with advanced Shy-Drager syndrome were treated with pergolide without benefit.

Address correspondence and reprint requests to Dr. Kurlan, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642.

Supported by a United Parkinson Foundation fellowship (Dr. Kurlan), the University of Rochester-Monroe Community Hospital Research Fund (Dr. Hamill), NINCDS Teacher Investigator Award (KO7 NS000397, Dr. Shoulson), the University of Rochester Clinical Research Center (RR-00044, NIH), and Eli Lilly Company.

Presented in part at the thirty-sixth annual meeting of the American Academy of Neurology, Boston, MA, April 1984.

Accepted for publication September 5, 1984.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.